Reply to “Reassessing 177 Lu-PSMA-617 Acquisition Costs: Implications for U.S. Radiopharmaceutical Therapy Cost-Effectiveness Analyses”
Year: 2026
Type: letter
Abstract: REPLY: We thank Flannery et al. and Subramanian and Osborne for their thoughtful letters regarding our cost-effectiveness analysis of 177Lu-PSMA-617 versus cabazitaxel ([1][1]). Both letters note the uncertainty surrounding U.S. costs for 177Lu-PSMA-617 therapy. As stated in our article, directly
Source: Journal of Nuclear Medicine
Language: English
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W7207808397